BCM
ADPT icon

BlueCrest Capital Management’s Adaptive Biotechnologies ADPT Stock Holding History

BlueCrest Capital Management’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-8,400
Closed -$260K – 380
2019
Q3 		$260K Sell
8,400
-16,600
-66% -$677K 0.02% 414
2019
Q2 		$1.21M Buy
+25,000
New +$1.11M 0.09% 137

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
SIG
Senator Investment Group New York $2.18B AUM 58.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $5.89B AUM 28.74% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TM
Tiger Management New York $22.8M AUM 0.71% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return

BlueCrest Capital Management's ADPT Position: Q4 2019 in Review

BlueCrest Capital Management sold out of Adaptive Biotechnologies (ADPT) in Q4 2019, closing a stake of 8,400 shares — an estimated $260K sold.

BlueCrest Capital Management first reported a position in ADPT in Q2 2019 and held it in 2 quarters. The position peaked at $1.21M in Q2 2019. 133 funds tracked by Wall St. Rank hold ADPT as of Q4 2019.

  • BlueCrest Capital Management reported no remaining Adaptive Biotechnologies position as of Q4 2019 after selling out during the quarter.
  • BlueCrest Capital Management sold 8,400 Adaptive Biotechnologies shares in Q4 2019, an estimated $260K.
  • BlueCrest Capital Management first reported a position in Adaptive Biotechnologies in Q2 2019 and held it in 2 quarters.
  • BlueCrest Capital Management's Adaptive Biotechnologies position peaked at $1.21M in Q2 2019.
  • 133 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q4 2019.

Based on BlueCrest Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.